Larimar Therapeutics Inc
LRMR
NASDAQ
Biotechnology
$4.36
USD
+0.09 (+2.11%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $445.14M
Volume 1.2M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-172.60M
TTM
-73.0%
YoY
Operating Cash Flow
$-155.92M
TTM
-69.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.4 | 4.6 | 4.6 | 6.1 | 6.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 27.8 | 49.5 | 64.0 | 31.1 | 34.4 |
Operating Income | -27.8 | -49.5 | -64.0 | -31.1 | -34.4 |
EBITDA | -27.7 | -49.4 | -63.9 | -31.1 | -34.3 |
Other Income / Expense | 1.6 | 1.8 | 1.5 | 1.5 | 1.6 |
Total Other Income / Expense | 1.6 | 1.8 | 1.5 | 1.5 | 1.6 |
Income Before Income Taxes | -26.2 | -47.7 | -62.5 | -29.6 | -32.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -26.2 | -47.7 | -62.5 | -29.6 | -32.8 |
Consolidated Net Income / Loss | -26.2 | -47.7 | -62.5 | -29.6 | -32.8 |
Net Income Attributable to Common Shareholders | -26.2 | -47.7 | -62.5 | -29.6 | -32.8 |
Basic EPS | -$0.41 | -$0.61 | -$0.73 | -$0.31 | -$0.30 |
Diluted EPS | -$0.41 | -$0.61 | -$0.73 | -$0.31 | -$0.30 |
Basic Shares Outstanding | 64.0M | 78.3M | 85.5M | 89.8M | 104.4M |
Diluted Shares Outstanding | 64.0M | 78.3M | 85.5M | 89.8M | 104.4M |